论文部分内容阅读
甲真菌病占皮肤真菌感染的３０％，占自然人群发病率的２％～５％。为了观察伊曲康唑短程、间歇冲击疗法治疗甲真菌病的疗效与安全性，我们于１９９３年１１月至１９９４年卫卫月应用比利时杨森公司生产的伊曲康唑胶囊，进行了为期１年的临床观察，现将结果总结如下。一、病例
Onychomycosis accounts for 30% of fungal skin infections, accounting for 2% to 5% of the natural population. In order to observe the efficacy and safety of itraconazole short-stroke, intermittent impact therapy for the treatment of onychomycosis, we conducted a one-year trial of itraconazole capsules from Jansen Co., Belgium from November 1993 to 1994 The clinical observations, the results are summarized below. First, the case